The Pan-African Paradigm of Bioethics and Health Sovereignty
Would a trial that withholds a proven vaccine from newborns for their first six weeks of life be approved in the country that funds it? That is the question at the center of a hepatitis B study, championed by US Health Secretary Robert F. Kennedy Jr., that won approval this week to go ahead in Guinea-Bissau. Danish researchers plan to enroll 14,000 infants. Half will receive the hepatitis B vaccine at birth. The other half will not receive it for the first six weeks of life.
The ethics committee at the researchers’ home institution, the University of Southern Denmark, voted this week to proceed. Officials in Guinea-Bissau have also approved the project, which the health minister, Quinhin Nantote, had said was suspended after an international outcry earlier this year.
The Disease Burden Behind the Debate
The stakes are high in Guinea-Bissau. About 18 percent of adults carry the hepatitis B virus, among the highest rates in the world. The virus can pass from mother to child at birth, but a parent, relatives, siblings, or caregivers can also transmit it. Children infected in the first year of life are significantly more likely to suffer severe outcomes, including chronic infection and liver cancer. Guinea-Bissau had planned to begin vaccinating all newborns against hepatitis B in 2027, and that campaign has since been pushed back to 2028.
Critics say this delay is what makes the trial possible: a gap in standard care that a research protocol can occupy. Paul Offit, an infectious disease physician at Children’s Hospital of Philadelphia, said the trial could never be run in the United States because of its significant ethical problems. “He’s taking advantage of a developing country,” Offit said of Robert F. Kennedy Jr. “Is it because children in Africa are more expendable than children here?” Kennedy and the Danish researchers, Offit said, were “taking advantage of that delay in practicing standard care to put these children at risk unnecessarily”.
Resignations in Copenhagen’s Shadow
The approval has split the Danish committee itself. Stig Børsen Hansen, a founding member and one of two reviewers who presented the study to the committee, resigned in protest on Friday, citing major ethical problems. “You are now enrolling newborns in a lottery to test a hypothesis,” he said. Children randomly assigned not to receive the birth dose, he argued, face the risk of hepatitis B infection in their earliest days, an infection that would, in effect, happen by design. Three other committee members have also resigned in protest.
Henrik Støvring, a professor of statistics and pharmacometrics at Aarhus University, said decades of research make the vaccine’s benefit clear, so it is unfair to place some children in an unvaccinated group. The study will look at vaccination and mortality, as well as outcomes such as skin and neurodevelopmental conditions. Støvring called this “something highly speculative,” in a situation where the World Health Organization and others say the vaccine should be given at birth.
A Revised Protocol, Still Not Public
The protocol has changed since it was posted in January, according to details shared with journalists; the revised version has not been made public. Mothers will now be tested for hepatitis B before giving birth. Babies of mothers who test positive will be vaccinated and left out of the trial, while babies of mothers who test negative may be enrolled. Critics say this does not resolve the core problem. In earlier research, half of the children who contracted hepatitis B did so after birth, through exposure in the community. The virus can survive on surfaces for up to seven days and spread through shared washcloths, toothbrushes and nail clippers. The maternal test also has a five percent false-negative rate.
Under the Declaration of Helsinki, international medical research must be approved by ethics committees in both the host and the sponsor countries. The Danish committee has now voted to proceed, and officials in Guinea-Bissau have given the project the green light. Whether the substance of that standard has been met, and not only its form, is what is now contested.
Money, Politics and the Bandim Connection
The trial is closely tied to US politics. It is a central part of the vaccine agenda of Kennedy, the US Secretary of Health and Human Services and a longtime vaccine opponent, whose administration has cut vaccine recommendations and cast doubt on the safety and effectiveness of shots. At an anti-vaccine conference last month, he praised the Danish researchers, calling them “the deities of vaccine research”. The US Centers for Disease Control and Prevention has reportedly set aside $1.6 million in this year’s budget for the project, a figure that has not been officially confirmed. The money is to be matched by private funding from the Pershing Square Foundation, co-founded by the billionaire activist Bill Ackman, and the Bluebell Foundation. The CDC, the researchers, Pershing Square and Minister Nantote had not responded to press questions at the time of writing.
The researchers, Peter Aaby and Christine Stabell Benn, run the Bandim Health Project, which has worked in Guinea-Bissau for decades and is deeply embedded in the country’s health system. At least one senior official, the current director of public health, held a dual appointment with Bandim as recently as December. The Africa Centers for Disease Control and Prevention has opposed the trial. One of its officials said this week there were “ongoing discussions” between the United States and Guinea-Bissau, with more details to come.
Closing: Health Sovereignty Is the Right to Say No
The asymmetry is plain. The funding, the ideological sponsorship, and the scientific hypothesis come from the North, while the risk falls on Bissau-Guinean newborns. Structural sovereignty in health is not just a ministry’s signature on an approval form. It is the institutional capacity to judge a protocol independently, to resist pressure from powerful patrons, and to put the national immunization schedule ahead of a foreign research agenda. Africa CDC’s opposition shows that a continental voice exists. Whether Guinea-Bissau can use it and bring forward the universal birth dose that would make the trial’s control group unnecessary will decide which way this goes.
